Mikael Hillgren

This inventor holds 6 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Acadia Pharmaceuticals Inc., Cinclus Pharma Holding Ab (Publ). Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mikael Hillgren. Retrieved from https://idiyas.com/inventor/mikael-hillgren

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 17(Granted Patents)

Location History:

Orebro, SE (2020 - 2023)
Uppsala, SE (2023)

Company Filing History:

4 out of 94

Acadia Pharmaceuticals Inc.

patents

2 out of 2

Cinclus Pharma Holding Ab (Publ)

patents

Years Active: 2020-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365680 - Polymorphs of the hydrochloride salt of linaprazan glurate (2025-07-22),

2. 11840515 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c (2023-12-12),

3. 11820772 - Polymorphs of the hydrochloride salt of linaprazan glurate (2023-11-21),

4. 10981871 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C (2021-04-20),

5. 10981870 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form (2021-04-20),

6. 10597363 - Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C (2020-03-24),

Title: Inventor Spotlight: Mikael Hillgren

Introduction: Mikael Hillgren is a notable inventor based in Uppsala, Sweden, recognized for his contribution to pharmaceutical science. With a passion for innovation, he has developed a patent that addresses significant health issues, particularly in the realm of gastrointestinal diseases.

Latest Patents: Mikael holds one patent titled "Polymorphs of the hydrochloride salt of linaprazan glurate." This invention pertains to the polymorphs of hydrochloride salt of linaprazan glurate, specifically Form 1 and Form 2 of the HCl salt. The patent also outlines a process for preparing these polymorphs and their applications in pharmaceutical compositions beneficial for treating or preventing gastrointestinal inflammatory diseases, including erosive gastroesophageal reflux disease (eGERD).

Career Highlights: Mikael is currently employed at Cinclus Pharma Holding AB, a company dedicated to advancing pharmaceutical innovations. His work in this company plays a crucial role in the development of new therapeutic options for patients suffering from gastric acid-related diseases.

Collaborations: Throughout his career, Mikael has collaborated with esteemed coworkers such as Kjell Jarring and Thomas Larsson. Their collective expertise contributes to the innovative environment at Cinclus Pharma and enhances the potential for groundbreaking advancements in the industry.

Conclusion: Mikael Hillgren exemplifies the spirit of innovation within the pharmaceutical sector. His patent on the polymorphs of linaprazan glurate is a significant step forward in addressing gastrointestinal inflammatory diseases. With ongoing collaborations and research, Hillgren’s contributions continue to have a positive impact on health and medicine.

Profile summary based on public USPTO records.